% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

  • codyoot codyoot Dec 19, 2012 4:33 PM Flag

    article from seeking alpha part I

    With its main sequencing platform product, the PacBio RS, customers of Pacific Biosciences are able to incorporate single molecule, real time analysis. They are also able to perform longer readlengths which is a unique aspect of the system. As noted in an article published by UCSD found here, the University believes that such a feature "will allow insights into biology that are not possible with existing technologies." As sequencing organisms becomes more complicated and detailed, the PacBio RS provides one of the leading solutions when it comes to capabilities. Longer readlengths allow a more comprehensive view of the genome and sequencing results can be reduced to less than a day.

    With a market capitalization of $92 million, Pacific Biosciences supplies genome centers, agricultural companies, government offices, and academic institutions with platforms that provide the unique detection of biological processes. The company has performed very poorly in recent years as it unveiled the PacBio RS but struck a rather upbeat note in its latest quarterly conference call found here. Having finally worked out its primary product's bugs and increased its backlog orders, management cites that the company's clients are beginning to turn to the PacBio RS in light of its advantages in a very niche market. The backing of academia and the renewed praise from clientele suggest that the company has begun to turn around after fixing its prior issues.

    Sentiment: Strong Buy

8.82-0.20(-2.22%)Sep 29 4:00 PMEDT